Metamizol y riesgo de agranulocitosis

Abstract

Metamizole or dipyrone is a drug that has been on the market for almost 100 years and is used for successful analgesic and antipyretic treatment. Agranulocytosis is a very serious complication that can appear in patients after the administration of metamizole, during or after treatment. There is a great geographic variability in the incidence of agranulocytosis, being higher in some northern European countries if we compare it with southern and South American countries. The fact that more has been diagnosed in these patients has suggested a predisposing hereditary factor, which is why some studies go in this direction. For this reason, there are many countries where its use is prohibited, others where it is dispensed with a prescription and others where the sale is free.